Jubilant in drug discovery pact with Janssen Pharma

Thomas K Thomas New Delhi. June 28 | Updated on June 28, 2011 Published on June 28, 2011

Jubilant Discovery Services Inc., a US based subsidiary of Jubilant Life Sciences Company, has entered into a drug discovery alliance with Janssen Pharmaceutica N.V. to deliver preclinical candidates to Janssen. The alliance is set to span an initial period of 3 years and will focus on multiple targets in the area of neuroscience.

Under the terms of the alliance agreement, Janssen will transfer ongoing efforts on selected drug discovery targets to Jubilant. Jubilant shall then carry out the research services and deliver preclinical candidates to Janssen for possible further development and commercialisation. In addition to receiving research funding, Jubilant may also be eligible to receive milestones and royalties should Janssen successfully develop and commercialise the candidates.

Mr Sri Mosur, CEO & President, Global Drug Discovery & Development, Jubilant said: “The collaboration will utilise Jubilant’s global research network to include our new research facility in the US focused in the area of neuroscience, in addition to our India-based research centres. We look forward to enhancing the research and development efforts at Janssen through this unique and creative alliance in these dynamic times in the industry".

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on June 28, 2011
This article is closed for comments.
Please Email the Editor